BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1838364)

  • 1. Clinical use of thymidine as a rescue agent from methotrexate toxicity.
    Grem JL; King SA; Sorensen JM; Christian MC
    Invest New Drugs; 1991 Aug; 9(3):281-90. PubMed ID: 1838364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
    van den Bongard HJ; Mathĵt RA; Boogerd W; Schornagel JH; Soesan M; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):537-40. PubMed ID: 11459208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure.
    Castro M
    J Clin Oncol; 2003 Nov; 21(21):4066. PubMed ID: 14581433
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine rescue of high-dose methotrexate in humans.
    Howell SB; Ensminger WD; Krishan A; Frei E
    Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
    Howell SB; Krishan A; Frei E
    Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management recommendations in patients with methotrexate intoxication].
    Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2007 Feb; 151(6):337-41. PubMed ID: 17352296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Pediatr Hematol Oncol; 1990; 7(4):347-63. PubMed ID: 2268535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence of methotrexate pharmacokinetics.
    Howell SB; Tamerius RK
    Eur J Cancer (1965); 1980 Nov; 16(11):1427-32. PubMed ID: 7227419
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe methotrexate toxicity precipitated by intravenous radiographic contrast.
    Harned TM; Mascarenhas L
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):496-9. PubMed ID: 17609630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal dysfunction during and after high-dose methotrexate.
    Green MR; Chamberlain MC
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate revisited.
    Frei E
    Med Pediatr Oncol; 1976; 2(3):227-41. PubMed ID: 790144
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevention of methotrexate toxicity by thymidine infusions in humans.
    Ensminger WD; Frei E
    Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion.
    Grindey GB; Semon JH; Pavelic ZP
    Antibiot Chemother (1971); 1978; 23():295-304. PubMed ID: 306219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.